Bayer’s rare cancer drug Aliqopa bags speedy approval
Bayer | September 18, 2017
US regulators have issued an accelerated approval for Bayer’s relapsed follicular lymphoma therapy Aliqopa. The decision allows physicians in the country to prescribe the drug to patients who have received at least two prior systemic therapies. Follicular lymphoma is a slow-growing type of non-Hodgkin lymphoma, a cancer of the lymph system, and despite being the most common form of NHL is considered a rare disease with unmet need.